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20 Abstract
21 Streptococcus mutans, a dental caries causing odontopathogen, produces X-prolyl dipeptidyl 
22 peptidase (Sm-XPDAP, encoded by pepX), a serine protease known to have a nutritional role. 
23 Considering the potential of proteases as therapeutic targets in pathogens, this study was 
24 primarily aimed at investigating the role of Sm-XPDAP in contributing to virulence-related 
25 traits. Dipeptidyl peptidase (DPP IV), an XPDAP analogous enzyme found in mammalian 
26 tissues,is a well known therapeutic target in Type II diabetes. Based on the hypothesis that 
27 gliptins, commonly used as anti-human-DPP IV drugs, may affect bacterial growth upon 
28 inhibition of Sm-XPDAP, we have determined their ex vivo antimicrobial and anti-biofilm 
29 activity towards S. mutans. All three DPP IV drugs tested reduced biofilm formation as 
30 determined by crystal violet staining. To link the observed biofilm inhibition to the human-DPP 
31 IV analogue present in S. mutans UA159, a pepX isogenic mutant was generated. In addition to 
32 reduced biofilm formation, CLSM studies of the biofilm formed by the pepX isogenic mutant 
33 showed these were comparable to those formed in the presence of saxagliptin, suggesting a 
34 probable role of this enzyme in biofilm formation by S. mutans UA159. The effects of both pepX 
35 deletion and DPP IV drugs on the proteome were studied using LC-MS/MS. Overall, this study 
36 highlights the potential of Sm-XPDAP as a novel anti-biofilm target and suggests a template 
37 molecule to synthesize lead compounds effective against this enzyme. 
38
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42 Introduction
43 Dental caries is the most prevalent, multifactorial, globally increasing oral health problem among 
44 children and adults (Bagramian et al., 2009; Selwitz et al., 2007). It is a manifestation of biofilm 
45 formation by certain members of the indigenous oral microbiota that are aciduric and acidogenic. 
46 Among them, Streptococcus mutans is one of the key etiological agents of dental caries. S. 
47 mutans is known to code for several peptidases and exoglycosidases that can facilitate utilization 
48 of human saliva as a source of nutrition (Ajdić et al., 2002). X-prolyl dipeptidyl aminopeptidase 
49 (XPDAP) is one such narrow substrate range cytoplasmic endopeptidase found in S. mutans, 
50 which help in utilization of proline-rich salivary polypeptides (Cowman and Baron, 1997, 1993). 
51 Collagenolytic and caseinolytic activities demonstrated by XPDAP further suggest its 
52 importance as a putative virulence factor in S. mutans (Cowman et al., 1975; Rosengren & 
53 Winblad, 1976). In Streptococcus suis and Streptococcus gordonii extracellularly present 
54 XPDAP play a role also in cellular invasion (Ge et al., 2009; Goldstein et al., 2001). Similarly, 
55 periodontal pathogen Porphyromonas gingivalis also had altered virulence in absence of XPDAP 
56 (Yagishita et al., 2001).
57 An analogous enzyme to XPDAP, DPP IV is also found in mammalian tissues and is a target for 
58 maintaining glucose homeostasis in Type II diabetic patients (Cowman and Baron, 1997; Green 
59 et al., 2006). Diabetes, an abnormal metabolic disorder, is an epidemic of significant healthcare 
60 concern among both developed and developing countries (King et al., 1998). Certain drugs, 
61 namely saxagliptin, vildagliptin and sitagliptin, are commonly used anti-human DPP IV (AHD) 
62 molecules used in the treatment of Type II diabetes (Green et al., 2006). DPP IV targets incretin 
63 hormones such as GLP-1, thereby decreasing their plasma levels. Inhibition of DPP IV leads to 
464 the opposite effect, which results in a restoration of glucose homeostasis in diabetic patients 
65 (Wang et al., 2012). As a novel approach, our recent investigation has shown that S. mutans 
66 XPDAP (Sm-XPDAP, encoded by pepX) is inhibited by saxagliptin in vitro (De et al., 2016). In 
67 an extension of this work and hypothesising a probable role of Sm-XPDAP in virulence, herein 
68 we have evaluated the ex vivo effect of these molecules on cell growth and biofilm formation by 
69 S. mutans. A pepX (SMU.35) isogenic mutant was also generated. Furthermore, whole cell 
70 proteome analysis of AHD treated cells and the isogenic mutant was performed to identify 
71 possible consequences of Sm-XPDAP inhibition or deletion.
72 Materials and Methods
73 MIC and Biofilm formation assay
74 The MIC was determined by microdilution assay according to the Clinical and Laboratory 
75 Standards Institute (CLSI, 2011), with the exception of the medium used, which was BHI (Ahn 
76 et al., 2012; da Silva et al., 2013). The highest concentration of 2048µg/mL of each AHD was 
77 serially diluted down to 4µg/mL and the final density of mid-exponential phase cells used was 
78 106 CFU/mL. The drugs were dissolved in sterile water and erythromycin was used as a positive 
79 control. 
80 Biofilm formation was assessed by a semi-quantitative crystal violet method in polystyrene 96-
81 well cell culture plates (Costar 3595; Corning Inc., NY) as previously described (Ahn et al., 
82 2008). An overnight culture of S. mutans UA159 (ATCC 700610) was transferred into pre-
83 warmed BHI and grown till mid-exponential phase and then diluted 50 fold in semi-defined 
84 biofilm medium (SDM) supplemented with 20mM glucose or sucrose. Aliquots (100µL) of this 
85 culture were added to serially diluted drug in water (2048µg/mL to 4µg/mL), to make a final 
586 volume of 200µL (with a 100-fold final dilution of cells) and incubated for 20 hours. The 
87 adhered cells were stained with 1% crystal violet for 15 minutes and the extract was quantified at 
88 495nm. The viability of the cells in the culture medium (planktonic phase over the formed 
89 biofilm) at each concentration of drug was determined by CFU counting.
90 Construction of pepX deletion mutants
91 A pepX deletion mutant was generated by PCR ligation mutagenesis method (Lau et al., 2002). 
92 Briefly, erythromycin cassette, upstream and downstream flanking regions (about 600bps) of 
93 pepX was amplified using specific primers (Table 2). The amplicons were digested using NcoI 
94 and SacI and ligated at 16⁰C overnight. The resulting ligation mixes were used for PCR to obtain 
95 a mutagenic construct using primers pepX-Up-F and pepX-Dn-R. This fragment was naturally 
96 transformed into mid-log phase S.mutans UA159, grown in Todd-Hewitt broth containing 10% 
97 sucrose and the recombinants were selected on BHI agar containing 10µg/mL erythromycin 
98 (Petersen and Scheie, 2000).The pepX mutant was confirmed by colony PCR and Sanger 
99 sequencing.
100 CLSM examination of Biofilm
101 The structure of biofilm of the pepX mutant and wild-type S. mutans, grown on polystyrene discs 
102 in the presence of SDM and glucose and AHD drugs as described above, was evaluated using an 
103 LSM-510-META laser scanning microscope attached to an Axioplan-II microscope (Zeiss). The 
104 non-adherent cells were washed in saline, biofilms were stained with Live/Dead BacLight-(1X) 
105 (Molecular Probes Inc.) for 20 minutes and rinsed three times in saline to remove excess stain. 
106 Subsequently, the stained discs were examined with an alpha Pan-Fluor 100X objective under 
107 excitation at 488nm (Argon-laser) and 543nm (He-Ne-laser), and emission filter ranging 585-
6108 615nm and 505-530nm for Propidium iodide and SYTO9, respectively. ImageJ v1.48 (NIH, 
109 USA) was used to process images. The proportion of viable cells (green) versus dead cells (red) 
110 was determined based on the intensity at each pixel using ImageJ (Nance et al., 2013). The 
111 proportion of green signal and the red signal was calculated by multiplying the total number of 
112 pixels with the given intensity (0 -255) at each channel and then dividing it by the sum of the 
113 intensity value for each signal measured at each image stack. 
114 Proteome analysis of biofilm-grown cells
115 The proteome of biofilm-grown cells in absence or presence of an AHD drug and that of the 
116 ΔpepX mutant were analysed from 48mL of culture. In brief, after 20 hours incubation, the 
117 harvested biofilm cells were lysed. The lysate was used to acetone precipitate all proteins 
118 overnight at -20°C. The precipitate was washed in 80% and 40% acetone successively, air dried 
119 and then partially pre-fractionated by 1D PAGE. The protein containing gel was stained, 
120 destained and sectioned into pieces for treatment in 100mM NH4HCO3 and acetonitrile (ACN) 
121 for complete removal of Coomassie stain. The gel slices were dehydrated in ACN and digested 
122 in 40µg/mL trypsin (Trypsin Gold, MS Grade, Promega) at 37°C overnight. Digestion was then 
123 stopped by adding 50% ACN (v/v) and 5% formic acid (v/v) with shaking for 30 min. The 
124 peptides-containing digested extract was removed and the gel pieces were further extracted in 
125 ACN and formic acid before freeze drying. The lyophilized peptide digest was mixed in 5% 
126 ACN and 0.1% formic acid (v/v) and then run in a LC-NanoPump coupled to a tandem mass 
127 spectrometer (Thermo-Q-Exactive attached to HPLC Ultimate-3000-RSLCnano system), 
128 through an Easy Spray C18 column (PepMap-RSLC, 75µm×500mm, Thermo Scientific) in a 
129 gradient solvent mixture of water and ACN containing 0.1% formic acid. The run was carried 
130 out for 215 minutes at a flow rate of 0.3µL/min with a scan range of 350–1800 m/z. The mass 
7131 spectrum data (MS and MS2) was then processed in Progenesis LC-MS v4.1 and the peptides 
132 identified in MASCOT database (Matrix Science, UK).
133 Statistical analysis
134 Statistical analysis was performed using the software Statgraphics Centurion ver. XV (Statpoint 
135 Technologies, Inc., Virginia, USA). Fitting of data was done using Origin ver. 8.1 (Origin Lab 
136 Corporation, MA, USA). Inhibition of biofilm formation data were fitted using a dose/response 
137 function (Boltzmann), according to the following equation (1):
138         (1)𝑦 = 𝐴2 +  𝐴1 ‒ 𝐴21 +  𝑒(𝑥 ‒ 𝐸𝐶50) 𝑑𝑥
139 where A2 and A1 are the maximum and minimum level of biofilm formed, respectively, and 
140 EC50 is the concentration of the drug affecting 50% biofilm formation. EC50 values from the four 
141 replicates of the same drug were derived and their mean calculated. Distribution of EC50 values 
142 of the same drug was checked for normality. Analysis of variance (ANOVA) test was run to 
143 compare means from different drugs and to check variance. Probability value threshold was set 
144 to 0.05. Multiple comparison analysis was performed between pairs of data sets (considered as 
145 independent), corresponding to biofilm formation level (OD490nm) at each and every 
146 concentration of the given drug. F-test (ANOVA) was used to test for the rejection of the null 
147 hypothesis (P < 0.05).
148
149
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8151 Results
152 AHD drugs inhibited biofilm formation by S. mutans
153 AHD drugs did not show a visible growth inhibition effect in the concentration range studied (4–
154 2048 µg/mL). In the presence of sucrose, S. mutans sessile growth was not affected by any of the 
155 drugs, whereas all three AHD drugs inhibited biofilm formation in the presence of glucose, albeit 
156 with different potency (Fig. 1A). At concentrations >128 µg/mL of saxagliptin, there was 50% 
157 reduction of biofilm formation. Vildagliptin inhibited biofilm formation at concentrations ≥ 
158 256µg/mL, while sitagliptin demonstrated at least 50% inhibition at 256µg/mL, albeit with a 
159 substantial increase in biofilm biomass at 2048µg/mL. The EC50 values of all drugs fell within 
160 the range of 128-512µg/mL. However, in the case of sitagliptin, the data point at 2048 µg/mL 
161 was not considered for fitting due to the anomalous behaviour at that concentration. While 
162 saxagliptin exhibited a more consistent inhibition pattern at concentrations ≥ 64 µg/mL, 
163 sitagliptin gave a sudden drop till saturation at 256-1024 µg/mL (Supplementary Fig.S1), as 
164 confirmed by the lower EC50 value (Table 1). In the case of saxagliptin and sitagliptin, the F-test 
165 (ANOVA) showed a statistically significant difference between the means at each concentration 
166 (psaxagliptin = 0.0013, psitagliptin = 0.0089).To determine which means are significantly different 
167 from which other and to analyse the difference in effect at various concentrations, a multiple 
168 sample pairwise comparison of the means of the four independent measurements of biofilm 
169 formation at each drug concentration (number of concentrations n = 11, from 0 to 2,048µg/mL) 
170 was performed (Supplementary Fig. S2). The apparent increase in biofilm formation at 
171 2048µg/mL of sitagliptin was found to be statistically relevant when compared with the biofilm 
172 biomass formed in presence of 128, 256, 512, and 1024 µg/mL of the drug (Supplementary Fig. 
173 S2b, cyan points). The differences observed in the presence of vildagliptin were not significant.  
9174 The cells in the planktonic phase over the formed biofilm at each concentration of drug were 
175 equally viable with colony count at 64µg/mL-2048µg/mL of each AHD treatment ranging 
176 between 109 to 1010 CFU/mL (Supplementary Fig. S3).The control group 
177 (8.23±1.7×108CFU/mL) differed by one order of magnitude from the colony counts at 
178 2048µg/mL of each drug (p = 0.043, unpaired student t-test, two-tailed). 
179 pepX mutant exhibited reduced biofilm biomass
180 The stronger effect of saxagliptin on biofilm compared to the other two AHD drugs, concomitant 
181 with a lower Ki of this drug against pure recombinant enzyme (De et al., 2016), suggested a 
182 probable role of pepX in influencing biofilm formation by S. mutans. To confirm a direct 
183 involvement of Sm-XPDAP in the biofilm development, a pepX mutant was generated. Crude 
184 extracts from the deletion mutant showed no amidolytic activity. The growth rate of the pepX 
185 deletion mutant was comparable to that of the wild type both in BHI (data not shown) and 
186 inSDM (Supplementary Fig. S4, P = 0.317 by ANOVA for the variable “growth rate”), however, 
187 the CFU of mutant significantly differed from that of the wild type hinting towards less viability 
188 of pepX mutant in SDM (Supplementary Fig. S4, P < 0.01 by ANOVA for the variable “growth 
189 rate”). The biofilm of the ∆pepX mutant in SDM containing glucose was reduced by 70% (SD = 
190 13.4%, n = 9, Fig. 1B), while a lower decrease was observed in presence of sucrose (20%; SD = 
191 3.8%, n = 3, data not shown).The planktonic phase over the biofilm of pepX mutant had more 
192 viable cells compared to wild type (Fig 1B, insert), which may indicate that the mutant cells 
193 aggregate or adhere to the surface of the well less efficiently with a high propensity to remain in 
194 suspension. The same was for biofilms formed in the presence of AHD (Supplementary Fig. S3).
195
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196 Sm-XPDAP deficiency and saxagliptin treatment induced stress in S. mutans
197 The adherence of wild-type S. mutans treated with saxagliptin or vildagliptin and that of the 
198 ∆pepX mutant determined at 4h did not show any difference when compared to the untreated 
199 wild-type.  At 20h, the wild-type demonstrated a thick and dense homogenous layer of 
200 aggregated cells, apparently more viable with few void spaces (15µm and 70.4% green cells, 
201 respectively), whereas the ∆pepX mutant exhibited a less organized thin layer of cells with more 
202 void spaces (9.6µm and 28.5% green cells) (Fig. 2). The effect of saxagliptin on wild-type was 
203 similar to that of ∆pepX. At 512 µg/mL saxagliptin, streptococci showed shorter dispersed chains 
204 and experienced apparent stress with a higher prevalence of propidium iodide stained cells (36%) 
205 (Fig. 3e and 3f). Vildagliptin also led to disaggregation of the biofilm compared to the untreated 
206 control, but streptococcal chains looked healthier (Fig.3g). S. mutans grown in the presence of 
207 2048µg/mL sitagliptin presented a biomass level comparable to the untreated cells. However, 
208 chains were relatively long, apparently under stress with no difference in aggregation and in the 
209 proportion of dead cells (Fig. 3h and 3i). 
210
211 pepX mutant exhibited downregulation of Cell Surface Antigen I/II
212 The proteomic analysis for differentially expressed proteins confirmed the absence of PepX in 
213 the ΔpepX mutant. Using relatively stringent criteria for protein identification (>1 peptide 
214 identified per protein in each biological replicate) only 9 proteins were found to be more 
215 abundant in the wild-type compared to the ΔpepX mutant (Supplementary Table S1) and no 
216 proteins were more abundant in the mutant compared to wild-type. Notably, the differentially 
217 expressed proteins included the Cell Surface Antigen I/II, a well-characterised adhesion protein 
11
218 of S. mutans (Jenkinson and Demuth, 1997). Notably, three of these 9 proteins were amino acid 
219 tRNA ligases. Comparison of control and sitagliptin-treated biofilms identified 6 proteins as 
220 more abundant in the controls and 26 as more abundant in the drug-treated cells. Likewise, 
221 comparison of control and saxagliptin-treated biofilms identified 6 proteins as more abundant in 
222 the controls (including three glycosyltransferases and levansucrase, which may affect biofilm 
223 matrix formation) and 23 as more abundant in the drug-treated cells. Two of the 
224 glycosyltransferases (SMU.910 and SMU.1005), upregulated in the controls compared to 
225 saxagliptin-treated biofilms, were upregulated in the sitagliptin-treated biofilms suggesting drug 
226 specific responses that may affect biofilm remodelling. Of 49proteins differentially expressed in 
227 either drug treatment, 12 were noted to be consistently altered in both (Supplementary Table S1) 
228 and were primarily involved in protein synthesis (n = 4) and various metabolic pathways (n = 7). 
229
230
231
232
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242 Discussion
243 The AHD drugs used in this study are highly selective human DPP IV inhibitors (Wang et al., 
244 2012). We hypothesize their effects on S. mutans by acting on Sm-XPDAP and regulating the 
245 behaviour of the bacterium, even though the drugs may have multiple enzyme targets. The ex 
246 vivo assays using these gliptins showed inhibition of S. mutans biofilm formation. It could be 
247 speculated that this may impair streptococcal activity in the oral cavity of diabetic patients on 
248 these medications, as a consequence of the excretion of these drugs in saliva. Saxagliptin and 
249 vildagliptin have been found to possess 50% and >90% oral bioavailability, respectively 
250 (Boulton et al., 2013; Villhauer et al., 2003), while saxagliptin has also been reported in the 
251 salivary gland tissue (Fred, 2009). Sitagliptin, which is quite effective against biofilm formation 
252 and classified as a high intestinal permeability and low protein binding drug, has been found in  
253 saliva (AUC 592 ng/mL×hr) (Idkaidek and Arafat, 2012). This may suggest the possibility of 
254 excretion of the other two AHD drugs in saliva, which in conjunction  with our results may 
255 suggest that systemic basal level of these drugs in host tissue of prescribed users may help in 
256 interfering with S. mutans behaviour. 
257 In view of the differential cell physiology in sessile form compared to planktonic phase, the very 
258 high MIC of AHD drugs was considered inconsequential. CLSM was performed to investigate 
259 the influence of AHD drugs and the effect of Sm-XPDAP deficiency on the structural 
260 organization of S. mutans biofilms in vitro. We tested saxagliptin and vildagliptin, the first for its 
261 gradual relative effect at each concentration and the second for its consideration as a reference 
262 molecule for comparison between “cyanopyrrolidides”. CLSM was conducted at 128 µg/mL 
263 saxagliptin and 512 µg/mL vildagliptin, which were the concentrations causing >40% biofilm 
264 inhibition (Fig. 1A). Blurred green cells observed under CLSM in biofilm treated with AHD was 
13
265 indicative of the stress experienced by S. mutans in the given condition (Boulos et al., 1999). 
266 Cells treated with 512 µg/mL saxagliptin displayed similar observation to that of pepX mutant, 
267 which may allow hypothesizing that the inhibition of biofilm in presence of AHD drugs may be 
268 exerted through Sm-XPDAP inhibition. In contrast to the other AHD drugs, a sudden increase in 
269 attached biofilm observed in presence of 2048µg/mL sitagliptin can likely be best explained due 
270 to increased stress response. Interestingly, there was complete inhibition of growth at the 
271 subsequent higher concentration of sitagliptin (Supplementary Fig. S5). A similar differential 
272 response to varying concentrations of the antibiotic lincomycin has also been reported in 
273 Streptococcus pyogenes (Malke et al., 1981), albeit the mechanism of action has not been 
274 explained yet. As a proof of concept, in this study we have used experimental systems as 
275 simplified as possible, considering that changes in variables may mask inhibition effects by the 
276 tested drugs. Once the fine mechanism of gliptin action in S. mutans is unravelled it will be of 
277 great interest to investigate how variations in the experimental approach that better emulate the 
278 in vivo conditions, such as using hydroxylapaptite discs, adding saliva or using a mixed species 
279 biofilm model could alter the drug activity.   
280 In this study a preliminary attempt was also made to identify a plausible role of PepX in 
281 modulating the proteome and investigate the site of action of AHD drugs in S. mutans through 
282 whole cell proteome analysis. Considering the high amount of biofilm biomass required for 
283 proteome analysis in parallel to undergoing investigations of the observed effect of AHD 
284 molecules, the analyses were performed at 128 µg/mL of saxagliptin and sitagliptin. Vildagliptin 
285 was exempted from the study due to its limited effect as observed by CLSM, whereas use of 
286 2048 µg/mL of sitagliptin was not feasible owing to the high amounts of pure molecule required. 
287 Surprisingly, relatively few differentially expressed proteins were consistently detected. 
14
288 Sitagliptin treatment and the pepX deletion both affected the expression of valine and proline 
289 amino acid tRNA-ligases, which may reflect perturbation of cytoplasmic amino acid pools and 
290 consequently an overall stress as observed under CLSM. The alteration of the level of cell 
291 surface antigen I/II (Okahashi et al., 1989) was of much interest, and this may correlate with the 
292 reduced hydrophobicity and biofilm formation exhibited by the mutant. The 12 proteins that 
293 were differentially expressed in response to both drug treatments were noted to include enolase 
294 (SMU.1247), which can be a moonlighting surface-associated protein in S. mutans (Ge et al., 
295 2004), and acetate kinase (SMU.1978), which participates in the Pta-Ack pathway that can 
296 influence biofilm formation (Kim et al., 2015).
297 Conclusions
298 Through this work we were able to establish a potential role of pepX in biofilm development of 
299 S.mutans and moved a step forward in the identification and development of novel Sm-DPP IV 
300 inhibitors. We have also tried to demonstrate the likely effect of AHD drugs on bacteria, as a 
301 proof of the concept that many regularly used drugs may exert some sort of side activity against 
302 microbes transiently or permanently inhabiting the human body. Future studies are focused on 
303 searching or synthesizing molecules targeting Sm-DPP IV that may be applicable as a new anti-
304 caries agent and studying the effect of drug molecules on S. mutans biofilms formed on 
305 hydroxylapatite discs and, ultimately, mixed species biofilms.
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414
415 Figure Legends
416 Fig.1.Quantification of biofilm formed by S. mutans in the presence of AHD drugs and of 
417 biofilm formed by a pepX deletion mutant. A. The histogram represents mean % biofilm 
418 formation in minimal medium containing 0-2048 µg/mL AHD drugs (n = 4, with duplicates 
419 within each independent experiment), B. Comparison of biofilm formation between ΔpepX (in 
420 black) and wild-type (in white) S. mutans in minimal medium containing glucose (n = 3, 
421 performed in triplicates within each independent experiment). Error bars represent standard 
422 deviation (p-value <0.001). Insert: viable cells count (expressed as CFU/mL) in the planktonic 
423 phase over the biofilm formed in SDM containing glucose.
424 Fig. 2. CLSM comparative study of biofilms formed by the ∆pepX mutant and wild-type S. 
425 mutans after 20 h. (a) ∆ pepX mutant (1st field), (b) ∆ pepX mutant (2nd field), (c) wildtype (1st 
426 field), (d) wild-type (2nd field), (e) z-axis representation of biofilm formed by ∆ pepX mutant, (f) 
427 z-axis representation of biofilm formed by wild-type. 
428 Fig. 3. CLSM images of S. mutans untreated controls and treated with AHD drugs. (a) Untreated 
429 (1st field), (b) Untreated (2nd field), (c) Untreated (3rd field), (d) 128µg/mL saxagliptin treated, 
430 (e) 512µg/mL saxagliptin treated (1st field), (f) 512µg/mL saxagliptin treated (2nd field), (g) 
431 512µg/mL vildagliptin treated, (h) 2048µg/mL sitagliptin treated (1st field), (i) 2048µg/mL 
432 sitagliptin treated (2nd field).  
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434 Tables 
435 Table 1. EC50 values for each drug. Mean concentration of drug producing 50% reduction in 
436 biofilm formation (EC50) was calculated from four independent replicates. Standard deviations 
437 (SD) were also determined.
Drug EC50 SD (µg/mL)
Saxagliptin 205  71
Vildagliptin 280  150
Sitagliptin 167  67
438
21
1 Table 2. Oligonucleotide DNA primers used in the present study.
Name Forward (5’  3’) Reverse (5’  3’) Purpose
Ery- 
pOMZ291
TAATCCATGGCACAAGTGATTTGTGATTGTTG TAATGAGCTCTAGGCGCTAGGGACCTCTTT Erythromycin cassette 
amplification
pepX-Up ATTGTCTTTTGCGTAGCATCTT TAATGAGCTCAAACCGTTCGTGATAACAGC 5’ fragment for pepX deletion
pepX-Dn TAATCCATGGAGGTCGCTAAGTTTGCTTTATTG TCCACAGCTGAGATAGTAGAGAATG 3’ fragment for pepX deletion
2
3
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2Fig.S1. Scatter plot of effect of each AHD molecule representing data points of four 
independent experiments (performed in duplicates within). Each data point 
corresponds to mean of the absorbance values (n = 2) at 495nm, at each concentration 
of AHD molecule while the data point at control or 0 µg/mL represents mean of 
absorbance values (n = 3) at the same wavelength. The absorbance values at 495 nm 
quantify the amount of extracted crystal violet by ethanol, in each biofilm assay. a. 
absorbance values at each concentration of saxagliptin, b. absorbance values at each 
concentration of vildagliptin, c. absorbance at each concentration of sitagliptin. 
3Fig.S2. Plots showing the pairwise estimated difference between means of the biofilm formed 
at two different concentrations of (a) Saxagliptin and (b) Sitagliptin. Statistical test 
was performed by multiple comparisons (all possible pairs of means) and Fisher's 
least significant difference (LSD) procedure. Pairs for which one mean was 
significantly different from the other (95% confidence level) were in red when 
positive and in cyan when negative. 
a b
4Fig. S3. Determination of cell viability of the planktonic phase in a biofilm assay at each 
concentration of AHD molecule. The platings were done in triplicates on BHI agar 
and mean of CFU/mL is reported as (‒) in the scatter plot. Sitagliptin (), 
Saxagliptin (■), Vildagliptin (▲).
5Fig. S4. Growth curves in SDM + glucose until 24 hrs incubation time. Circles: Colony 
Forming Units/mL (CFU/mL); Triangles: Optical Density units at 600 nm/mL (OD600/mL). 
Filled: wildtype (S. mutans UA159); Open: pepX mutant.
6Fig. S5.  Images and biofilm forming assay using crystal violet semiquantitative method at 
higher concentrations of sitagliptin. A sudden upsurge of biofilm formation at 2048 
µg/mL of sitagliptin is represented as images. A. before washing of unattached 
cells, B. after three washes of unbound cells using saline, and C. after crystal violet 
staining and two subsequent washes.  
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7Supplementary Texts
Text 1. Preparation of Semi-Defined biofilm medium (SDM)
Semi-Defined biofilm medium either in 20mM glucose or sucrose contained 58mM 
K2HPO4, 15mM KH2PO4, 10mM (NH4)2SO4, 35mM NaCl, 0.2% Casamino acids and 
filter sterilized 40µM Nicotinic acid, 100µM Pyrridoxine HCl, 10µM Pantothenic acid, 1µM 
Riboflavin, 0.3µM Thiamine HCl, 0.05µM D-Biotin, 4mM L-Glutamic acid, 1mM L-
Arginine HCl, 1.3mM L-Cysteine HCl, 0.1mM L-Tryptophan, 2mM MgSO4.7H2O. While 
preparation, salts and glucose or sucrose were autoclaved separately, whereas filter sterilized 
amino acids and vitamins were added in the medium at room temperature.
Text 2. Proteome analysis of biofilm grown cells
Protein isolation and pre-fractionation
The proteome of biofilm grown cells, either in absence or presence of an AHD drug, and that 
of the ΔpepX mutant were analysed from 48mL of culture. The biofilm for each condition 
was set up in a 24 well cell culture plate (Greiner Bio-one, CELLSTAR) as described above. 
After 20 hours of incubation the planktonic phase was removed and the attached biofilm was 
disrupted using sterile water. The harvested cells were pooled and washed twice in PBS (1X), 
resuspended in lysis buffer and sonicated at 12000 – 13000 microns amplitude for 2 minutes 
with an intermittent 10 sec on and 10 sec off in ice. Subsequently, the cell free extract was 
collected by centrifugation at 14000 × g for 45 min at 4°C and acetone precipitated at -20°C 
overnight. The precipitated proteins were collected by centrifugation, washed in 80% and 
40% acetone successively, air dried for 1 hour at room temperature and stored at -20°C for 
further use. The pellet was dissolved in 30mM Tris buffer (pH 8) and then partially pre-
fractionated by 1D PAGE. A similar amount of calculated protein (µg) as estimated by 
8Bradford assay, representing samples at each condition, was boiled with 5µL of loading dye 
for 15 min and electrophoresed at 200V for about 1 hr. The gel was stained in Coomassie 
Blue for 15 min followed by destaining overnight at room temperature. 
Sample preparation and Mass spectrometry
The protein containing gel was sectioned into pieces and then treated twice with 100mM 
NH4HCO3 and acetonitrile (ACN) with shaking for 30 min allowing removal of the 
Coomassie stain. The gel slices were then dehydrated in ACN at room temperature for 60 
min, air dried for 15 min and pre-incubated in 40µg/mL trypsin (Trypsin Gold, MS Grade, 
Promega) at 37°C for 1 hour in a water-bath. Subsequently, the gel pieces were immersed in 
NH4HCO3 and incubated further at 37°C overnight. On the following day, the digestion was 
stopped by adding 50% ACN (v/v) and 5% formic acid (v/v) with shaking for 30 min. The 
digested extract containing peptides was removed and transferred into a fresh vial (Fraction 
A). The gel pieces were further extracted using 83% ACN (v/v) and 0.2% formic acid under 
the same conditions (Fraction B). All the extracts containing digested peptides were then 
pooled (Fraction A + Fraction B) and frozen at -80°C for more than an hour. Frozen peptide 
digests were freeze-dried for 20- 24 hours (Alpha 1-2 LoPlus CHRIST attached to JAVAC 
High Vacuum pump). The samples were stored at -80°C until injection into the LC-MS/MS. 
Before injection, the lyophilized peptide digest was mixed in 5% ACN and 0.1% formic acid 
(v/v) and then run in a LC- NanoPump coupled to a tandem mass spectrometer (Thermo Q 
Exactive attached to HPLC Ultimate 3000 RSLC nano system), through an Easy Spray C18 
column (PepMap RSLC, 75µm × 500mm, Thermo Scientific) equipped with Electro Spray 
Ionization, in a gradient solvent mixture of water and ACN containing 0.1% formic acid. The 
run was carried out for 215 minutes at a flow rate of 0.3µL/min with a scan range of 350 – 
1800 m/z.  
9Identification of the peptides
The mass spectrum data (MS and MS2) obtained for each set of conditions was then 
processed in Progenesis LC-MS v4.1. The statistically validated peptides (>2 fold change in 
expression and features significantly present in all of the three technical replicates, p < 0.05) 
were exported into MASCOT database for identification (Matrix Science, www.matrix-
science.com). The database search was performed for MS/MS spectra of all selected peptides 
with carbamidomethyl and oxidised methionine as modifications, and peptide mass tolerance 
of ±20 ppm.  After identification, peptides were imported back into Progenesis for refining 
for only those protein matches from S. mutans, reviewing and removing all the proteins with 
conflict, grouping all the peptides with similar protein labels, quantifying abundance level of 
proteins and producing a compiled report on the differential level of proteins at different 
conditions.  To ensure robust protein identification, only those proteins consistently detected 
in both biological replicates, typically with a minimum of >1 peptide per protein in each run, 
were retained for further analysis.
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Supplementary Tables
Table S1. Differentially expressed protein identified by proteomic analysis of S. mutans biofilms (** 
these protein were only identified on the basis of 1 peptide in one of the biological replicates).
More abundant in SAXAGLIPTIN control cells
Protein id. Protein name/annotation  Expression ratio n=2
SMU.446 Glycine--tRNA ligase beta subunit  1.8
SMU.910 Glucosyltransferase-S 2.1
SMU.1004 Glucosyltransferase-I 2.1
SMU.1005 Glucosyltransferase-SI 2.5
SMU.2028 Levansucrase (ftf) 2.2
SMU.2031 Elongation factor Ts 2.1
More abundant in SAXAGLIPTIN treated cells
Protein id. Protein name/annotation  Expression ratio n=2
SMU.23 Ribose-phosphate pyrophosphokinase 1 1.6
SMU.34 Phosphoribosylformylglycinamidine cyclo-
ligase 
1.8
SMU.359 Elongation factor G 2.0
SMU.361 Phosphoglycerate kinase 2.1
SMU.402 Formate acetyltransferase (pfl) 2.6
SMU.421 Translation initiation factor IF-2** 2.1
SMU.471 Cell cycle protein GpsB 1.8
SMU.558 Isoleucine--tRNA ligase 3.6
SMU.676 NADP-dependent glyceraldehyde-3-
phosphate dehydrogenase 
1.7
SMU.712 Phosphoenolpyruvate carboxylase** 2.7
SMU.714 Elongation factor Tu 2.4
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SMU.860 Carbamoyl-phosphate synthase large 
chain**
2.6
SMU.1060 Signal recognition particle protein 2.3
SMU.1066 GMP synthase [glutamine-hydrolyzing] 2.0
SMU.1115 L-lactate dehydrogenase 2.0
SMU.1247 Enolase 1.9
SMU.1656 Phosphoserine aminotransferase 2.1
SMU.1673 Uracil phosphoribosyltransferase 2.5
SMU.1838 Protein translocase subunit SecA 1.8
SMU.1954 60 kDa chaperonin (groEL) 1.8
SMU.1978 Acetate kinase** 2.6
SMU.2101 Aspartate--tRNA ligase 2 2.1
SMU.2135c 30S ribosomal protein S4 7.5
More abundant in SITAGLIPTIN control cells
Protein id. Protein name/annotation  Expression 
ratio n=2
SMU.307 Glucose-6-phosphate isomerase  1.86
SMU.1457 dTDP-glucose 4,6-dehydratase 2.6
SMU.1770 Valine-tRNA ligase 28.0
SMU.1783 Proline-tRNA ligase 2.5
SMU.1786 Isoprenyl transferase 3.8
SMU.2031 Elongation factor Ts 1.6
More abundant in SITAGLIPTIN treated cells
Protein id. Protein name/annotation Expression 
ratio n=2
SMU.23 Ribose-phosphate pyrophosphokinase 1 4.3
12
SMU.82 Chaperone protein DnaK 3.3
SMU.155 Polyribonucleotide nucleotidyltransferase 5.3
SMU.359 Elongation factor G 2.0
SMU.402 Formate acetyltransferase (pfl) 2.19
SMU.421 Translation initiation factor IF-2 3.6
SMU.712 Phosphoenolpyruvate carboxylase 1.8
SMU.714 Elongation factor Tu 3.0
SMU.856 Bifunctional protein PyrR 2.6
SMU.860 Carbamoyl-phosphate synthase large chain 1.7
SMU.900 4-hydroxy-tetrahydrodipicolinate reductase 2.4
SMU.910 Glucosyltransferase-S 2.9
SMU.1005 Glucosyltransferase-SI 9.0
SMU.1085 Peptide chain release factor 1 32.1
SMU.1247 Enolase 4.5
SMU.1467 Adenine phosphoribosyltransferase 16.4
SMU.1538 Glucose-1-phosphate adenylyltransferase 6.3
SMU.1635 Bifunctional protein GlmU 1.9
SMU.1673 Uracil phosphoribosyltransferase 4.0
SMU.1820c Glutamyl-tRNA(Gln) amidotransferase subunit A ∞
SMU.1954 60 kDa chaperonin 34.4
SMU.1978 Acetate kinase** 3.1
SMU.1990 DNA-directed RNA polymerase subunit beta 3.5
SMU.1992 Tyrosine--tRNA ligase 9.1
SMU.2032 30S ribosomal protein S2 1.8
SMU.2128 Dihydroxy-acid dehydratase 2.3
13
More abundant in wild type compared to pepX mutant
Protein id. Protein name/annotation  Expression 
ratio n=2
SMU.82 Chaperone protein DnaK 2.2
SMU.610 Cell surface antigen I/II (spaP) 1.8
SMU.675 Phosphoenolpyruvate-protein phosphotransferase (ptsI) 1.8
SMU.1073 Formate-tetrahydrofolate ligase (fhs) 1.7
SMU.1770 Valine-tRNA ligase** 3.4
SMU.1783 Proline-tRNA ligase** 1.8
SMU.1838 Protein translocase subunit SecA 2.0
SMU.2008 50S ribosomal protein L30 2.5
SMU.2098 Arginine-tRNA ligase 2.5
